Mineral and Bone Disease (MBD) on a Kidney Transplant Patient

A 50-year-old post-menopausal recipient of a kidney allograft with bone pain, osteoporosis, persistent hypercalcaemia and elevated parathormone (PTH) levels, despite a satisfactory graft function, was treated with bisphosphonates and cinacalcet starting, respectively, 5 and 6 months after renal tran...

ver descrição completa

Detalhes bibliográficos
Autor principal: Birne, R (author)
Outros Autores: Adragão, T (author), Ferreira, A (author), Dickson, J (author), Silva, R (author), Casqueiro, A (author), Oliveira, R (author), Martins, AR (author), Torres, J (author), Matias, P (author), Branco, P (author), Jorge, C (author), Weigert, A (author), Bruges, M (author), Machado, D (author)
Formato: article
Idioma:eng
Publicado em: 2014
Assuntos:
HCC NEF
Biópsia
Hipercalcemia
Transplantação de Rim
Osteoporose
Texto completo:http://hdl.handle.net/10400.17/1794
País:Portugal
Oai:oai:repositorio.chlc.min-saude.pt:10400.17/1794
Descrição
Resumo:A 50-year-old post-menopausal recipient of a kidney allograft with bone pain, osteoporosis, persistent hypercalcaemia and elevated parathormone (PTH) levels, despite a satisfactory graft function, was treated with bisphosphonates and cinacalcet starting, respectively, 5 and 6 months after renal transplantation (RT). Sixteen months after treatment, there was improvement of bone mineral density (BMD) measured by dualenergy X-ray absorptiometry (DEXA). A bone biopsy was taken, unveiling a surprising and worrisome result. Post-RT bone disease is different from classic CKD-MBD and should be managed distinctly, including, in some difficult cases, an invasive evaluation through the performance of a bone biopsy, as suggested in the KDIGO guidelines.

Registros relacionados